STOCK TITAN

Seres Therapeutics, Inc. - $MCRB STOCK NEWS

Welcome to our dedicated page for Seres Therapeutics news (Ticker: $MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Seres Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Seres Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.55%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.58%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.86%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.87%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.85%
Tags
Seres Therapeutics, Inc.

Nasdaq:MCRB

MCRB Rankings

MCRB Stock Data

167.62M
119.11M
5.68%
59.45%
12.45%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About MCRB

seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.